The content is available as a PDF (537.6 KB).
letter . 2021 May 24:ciab480. doi: 10.1093/cid/ciab480
It is time to determine Tocilizumab place in COVID-19
Timothée Klopfenstein
1,✉, Aurélie Gerazime
2, Marc Puyraveau
2, N’dri Juliette Kadiane-Oussou
1, Vincent Gendrin
1, Souheil Zayet
1; For the HNF Hospital tocilizumab multidisciplinary team1
Timothée Klopfenstein
1Infectious Disease Department, Nord Franche-Comté Hospital, France
Find articles by Timothée Klopfenstein
Aurélie Gerazime
2Methodology unit, clinical investigation center INSERM 1431, Jean-Minjoz University Hospital, Besançon, France
Find articles by Aurélie Gerazime
Marc Puyraveau
2Methodology unit, clinical investigation center INSERM 1431, Jean-Minjoz University Hospital, Besançon, France
Find articles by Marc Puyraveau
N’dri Juliette Kadiane-Oussou
1Infectious Disease Department, Nord Franche-Comté Hospital, France
Find articles by N’dri Juliette Kadiane-Oussou
Vincent Gendrin
1Infectious Disease Department, Nord Franche-Comté Hospital, France
Find articles by Vincent Gendrin
Souheil Zayet
1Infectious Disease Department, Nord Franche-Comté Hospital, France
Find articles by Souheil Zayet
1Infectious Disease Department, Nord Franche-Comté Hospital, France
2Methodology unit, clinical investigation center INSERM 1431, Jean-Minjoz University Hospital, Besançon, France
✉
Corresponding author: Timothée Klopfenstein, Department of Infectious Disease, Nord Franche-Comté Hospital, 90400 Trevenans, France, E-mail: timothee.klopfenstein@hnfc.fr
Received 2021 Mar 16.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8194799 PMID: 34036334
This article has been corrected. See Clin Infect Dis. 2023 Mar 4;76(5):965.
See the article "The impact of tocilizumab on the mortality of patients with COVID-19" in volume 72 on page e1156.